MediWound to Present at Upcoming Investor Conferences

MediWound Ltd. (Nasdaq: MDWD), a leading biotechnology firm specializing in next-generation enzymatic therapeutics for tissue repair, has announced its participation in two noteworthy upcoming investor conferences. The presentations aim to highlight the company's advancements in non-surgical therapies and its innovative product offerings.

The first event, the Oppenheimer 36th Annual Healthcare Life Sciences Conference, will take place virtually on Thursday, February 26, 2026, at 10:40 a.m. ET. The second conference, the TD Cowen 46th Annual Health Care Conference, is scheduled for Monday, March 2, 2026, at 1:10 p.m. ET at the Boston Marriott Copley Place in Boston, MA. Both conferences will provide a platform for MediWound's management team to share insights on the company’s vision and growth trajectory.

MediWound is recognized for its groundbreaking enzymatic treatments, particularly its FDA-approved product, NexoBrid®. This biologic is specifically designed for the enzymatic removal of eschar in thermal burns and is marketed across various global regions, including the U.S., the European Union, and Japan. Furthermore, the company has a promising late-stage pipeline product, EscharEx®, which is an investigational therapy targeting chronic wounds. With potential applications in wound management, EscharEx® could redefine standards of care in this critical area.

Investors and interested parties can access live webcasts of each presentation through the Events & Presentations section on MediWound's official website. The company encourages stakeholders to follow its updates via LinkedIn and X (formerly Twitter) for the latest information and developments. For further inquiries, MediWound’s leadership can be contacted directly.

MediWound Ltd. (Nasdaq: MDWD) is positioning itself for potential investor interest with its upcoming presentations at several notable healthcare conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference. These appearances provide an optimal platform for the management team to articulate the company's strengths, especially its innovative enzymatic therapies designed for tissue repair.

Investors should closely monitor MediWound’s presentation for insights into its growth strategy and the advancement of its product pipeline, particularly its flagship product, NexoBrid®, which has already gained FDA approval. This product’s success in the market demonstrates MediWound's capabilities and serves as a strong foundation for investor confidence. Further, the investigational product EscharEx®, aimed at chronic wound debridement, is of particular interest as it could significantly alter the standard of care in wound management if approved. The potential market impact of EscharEx® in addressing chronic wounds—an area with considerable unmet need—could be a pivotal talking point at these investor gatherings.

Analysts should pay attention to the company’s financial guidance, updates on clinical trial timelines, and any strategic partnerships or collaborations disclosed. Such information holds the potential to impact stock performance significantly.

With a solid track record and promising pipeline, investors may view MediWound as a high-potential opportunity in the biotech sector, particularly as the healthcare landscape increasingly values innovative and effective therapeutic solutions. Given the company's upcoming engagements, a strategic entry point may present itself for those looking to invest in a company poised at the cutting edge of tissue repair technology. It’s advisable to follow these presentations closely and assess the resulting analyst recommendations and market reactions.